Bright Minds Biosciences (DRUG) Stock Forecast & Price Target

Compare

250 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DRUG Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

Bright

Minds Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DRUG Stock 12 Month Forecast

Average Price Target

$89.15

▲(5.89% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Bright Minds Biosciences in the last 3 months. The average price target is $89.15 with a high forecast of $114.33 and a low forecast of $71.58. The average price target represents a 5.89% change from the last price of $84.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","70":"$70","115":"$115","47.5":"$47.5","92.5":"$92.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":114.3293281254193,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$114.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.14568919,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.58010108721903,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$71.58</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,47.5,70,92.5,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.25,73.64071754810918,77.03143509621836,80.42215264432753,83.8128701924367,87.20358774054588,90.59430528865506,93.98502283676424,97.37574038487341,100.76645793298259,104.15717548109177,107.54789302920094,110.93861057731013,{"y":114.3293281254193,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.25,71.70351455307693,73.15702910615384,74.61054365923077,76.06405821230769,77.51757276538461,78.97108731846154,80.42460187153846,81.87811642461538,83.3316309776923,84.78514553076923,86.23866008384616,87.69217463692307,{"y":89.14568919,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.25,70.35231546824762,70.45463093649524,70.55694640474286,70.65926187299047,70.7615773412381,70.8638928094857,70.96620827773333,71.06852374598094,71.17083921422856,71.27315468247618,71.3754701507238,71.47778561897141,{"y":71.58010108721903,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.75,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$114.33

Average Price Target$89.15

Lowest Price Target$71.58

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$85→$115

Buy

36.60%

Upside

Reiterated

12/10/25

H.C. Wainwright Keeps Their Buy Rating on Bright Minds Biosciences (DRUG)for Bright Minds Biosciences (DRUG; Buy), we raise our price target to $115 (from $85) to reflect increases in the probability of success (POS) for BMB-101 driven by multi-year 5-HT2C validation

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$75→$82

Buy

-2.60%

Downside

Reiterated

11/07/25

Bright Minds price target raised to $82 from $75 at BairdBright Minds price target raised to $82 from $75 at Baird

Thomas Shrader

BTIG

$72

Buy

-14.48%

Downside

Reiterated

10/01/25

BTIG Remains a Buy on Bright Minds Biosciences (DRUG)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

09/25/25

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

07/02/25

Bright Minds assumed with an Overweight at Cantor FitzgeraldBright Minds assumed with an Overweight at Cantor Fitzgerald

Rudy Li

Chardan Capital

$80

Buy

-4.98%

Downside

Reiterated

05/21/25

Bright Minds Biosciences (DRUG) Receives a Buy from Chardan Capital

Yasmeen Rahimi

Piper Sandler

$93

Buy

10.46%

Upside

Reiterated

04/30/25

Piper Sandler Reaffirms Their Buy Rating on Bright Minds Biosciences (DRUG)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$85→$115

Buy

36.60%

Upside

Reiterated

12/10/25

Unknown Analyst

Robert W. Baird

Not Ranked

Robert W. Baird

$75→$82

Buy

-2.60%

Downside

Reiterated

11/07/25

Bright Minds price target raised to $82 from $75 at BairdBright Minds price target raised to $82 from $75 at Baird

Thomas Shrader

BTIG

$72

Buy

-14.48%

Downside

Reiterated

10/01/25

BTIG Remains a Buy on Bright Minds Biosciences (DRUG)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

09/25/25

Pete Stavropoulos

Cantor Fitzgerald

―

Buy

―

Initiated

07/02/25

Bright Minds assumed with an Overweight at Cantor FitzgeraldBright Minds assumed with an Overweight at Cantor Fitzgerald

Rudy Li

Chardan Capital

$80

Buy

-4.98%

Downside

Reiterated

05/21/25

Bright Minds Biosciences (DRUG) Receives a Buy from Chardan Capital

Yasmeen Rahimi

Piper Sandler

$93

Buy

10.46%

Upside

Reiterated

04/30/25

Piper Sandler Reaffirms Their Buy Rating on Bright Minds Biosciences (DRUG)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bright Minds Biosciences

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+3.43%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.43% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+40.93%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +40.93% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

3/3 ratings generated profit

Average Return

+142.83%

reiterated a buy rating 8 months ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +142.83% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+142.83%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +142.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DRUG Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DRUG has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DRUG average Analyst price target in the past 3 months is 89.15.

Each month's total comprises the sum of three months' worth of ratings.

DRUG Financial Forecast

DRUG Earnings Forecast

Next quarter’s earnings estimate for DRUG is -$0.57 with a range of -$0.90 to -$0.08. The previous quarter’s EPS was -$0.54. DRUG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DRUG has Performed in-line its overall industry.

No data currently available

DRUG Sales Forecast

Next quarter’s sales forecast for DRUG is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DRUG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DRUG has Performed in-line its overall industry.

DRUG Stock Forecast FAQ

What is DRUG’s average 12-month price target, according to analysts?

Based on analyst ratings, Bright Minds Biosciences’s 12-month average price target is 89.15.

What is DRUG’s upside potential, based on the analysts’ average price target?

Bright Minds Biosciences has 5.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DRUG a Buy, Sell or Hold?

Bright Minds Biosciences has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Bright Minds Biosciences’s price target?

The average price target for Bright Minds Biosciences is 89.15. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $114.33 ,the lowest forecast is $71.58. The average price target represents 5.89% Increase from the current price of $84.19.

What do analysts say about Bright Minds Biosciences?

Bright Minds Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of DRUG?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Bright Minds Biosciences (DRUG) Stock Forecast & Price Target

DRUG Analyst Ratings

DRUG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bright Minds Biosciences

DRUG Analyst Recommendation Trends

DRUG Financial Forecast

DRUG Earnings Forecast

DRUG Sales Forecast

DRUG Stock Forecast FAQ

Detailed List of Analyst Forecasts